Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
暂无分享,去创建一个
T. Conroy | E. Van Cutsem | J. Tabernero | A. Figer | P. Schőffski | C. Twelves | J. Cassidy | C. Butts | E. Díaz-Rubio | A. Sobrero | J. Grossmann | R. Brunet | F. D. Braud | F. Braud
[1] A. Gambardella,et al. A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108. , 2005, Critical reviews in oncology/hematology.
[2] R. Labianca,et al. The role of uracil-tegafur (UFT) in elderly patients with colorectal cancer. , 2004, Critical reviews in oncology/hematology.
[3] W. Scheithauer,et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] J. Feliu,et al. A phase II study of capecitabine (X) in elderly patients (p) as 1st line treatment for patients (pts) with advanced or metastatic colorectal cancer (MCRC) , 2004 .
[5] H. Botto. Combination of oxaliplatin (OXA) and 5-fluorouracil, leucovorin (5-FU/LV), as first line therapy, in elderly patients >70years, with metastatic colorectal cancer , 2004 .
[6] W. Scheithauer,et al. Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts) , 2004 .
[7] E. Lin,et al. Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial , 2004 .
[8] J. Feliu,et al. XELOX (capecitabine and oxaliplatin) as 1st line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Aapro,et al. Oxaliplatin (with 5FU and leucovorin ) in patients above age 70 ( «elderly» ) suffering from metastatic colorectal cancer: An observational study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Abad,et al. Biweekly irinotecan (CPT-11) plus 5-FU as first-line chemotherapy for elderly patients with metastatic colorectal cancer (MCRC). Final results of the Spanish Digestive Group (TTD) study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] W. Scheithauer,et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a phase III trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] T. Conroy,et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Alliot,et al. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly , 2004, British Journal of Cancer.
[14] D. Kuter. Thrombotic complications of central venous catheters in cancer patients. , 2004, The oncologist.
[15] R. Schilsky,et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials , 2004, British Journal of Cancer.
[16] C. Tournigand,et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Daniel J Sargent,et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Neugut,et al. Management of Colorectal Cancer in Elderly Patients , 2004, Drugs & aging.
[19] W. Scheithauer,et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] G. Agnelli,et al. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] H. Mackay,et al. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] Joy H. Lewis,et al. Participation of patients 65 years of age or older in cancer clinical trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Douillard,et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] A. Oza,et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] R. Schilsky,et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] R. Labianca,et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. , 2001, The New England journal of medicine.
[27] C. Wilson,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] C. Coltman,et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.
[29] C. Louvet,et al. 5-fluorouracile bimensuel en traitement du cancer colorectal métastasé chez le sujet âgé. Étude de 50 patients , 1999 .
[30] A. Norman,et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] A. Buzdar,et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.